| Literature DB >> 25935108 |
Angela Simpson1, Nevena Lazic2, Danielle C M Belgrave3, Phil Johnson4, Christopher Bishop2, Clare Mills4, Adnan Custovic5.
Abstract
BACKGROUND: The relationship between sensitization to allergens and disease is complex.Entities:
Keywords: IgE; allergens; asthma; childhood; component-resolved diagnostics; eczema; hay fever; latent variable modeling; wheeze
Mesh:
Substances:
Year: 2015 PMID: 25935108 PMCID: PMC4649774 DOI: 10.1016/j.jaci.2015.03.027
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793
Fig 1A, Specific IgE for each child to each allergen (quaternary scale, color coded: black, negative; yellow, low; orange, medium; and red, high). Allergen components are sorted according to CG membership, and children are sorted according to CG sensitization. B, Probability of each allergen component belonging to each CG (grayscale) based on the posterior distribution, indicating that for the 61 allergen components assigned to a CG, the probability was generally high (white, usually >0.9) C, Probability of each child being sensitized to each of the CGs (grayscale) based on the posterior sensitization probabilities, showing that children were frequently sensitized to more than 1 CG and that all combinations of sensitization were seen.
Allergen components within each CG
| CG | Pfam protein family | ISAC component |
|---|---|---|
| CG1 | β-Expansins (including N- and C-terminal domains) | C- and N-terminal domains: |
| Ribonuclease | ||
| Berberine bridge (FAD binding) | ||
| Profilin | ||
| Bet v 1 like (PR10) | ||
| Ole e 1 family | ||
| CCD | Jug r 2, MUXF3 | |
| Glycosylhydrolase family 28 (polygalacturonase and pectate lyase) | ||
| CG2 | MD-2–related lipid recognition (ML) domain (group 2 mite allergens) | rDer p 2, rDer f 2, rLep d 2 |
| Cysteine protease | nDer p 1, nDer f 1, nAct d 1 | |
| Mite allergen family 5 | rBlo t 5 | |
| CG3 | Prolamin | rAra h 2, nAra h 6, nJug r 3, rPru p 3 |
| Cupin | rAra h 1, rAra h 3, nGly m 6 | |
| EF hand | ||
| Thaumatin family | nAct d 2 | |
| Lipocalin | rCan f 1, rCan f 2, rEqu c 1, rFel d 4, Mus m1 | |
| Serum albumin | nBos d 6, nCan f 3, nEqu c 3, nFel d 2 | |
| Uteroglobulin-like | rFel d 1 | |
| Kazal-type inhibitor | nGal d 1 | |
| Tropomyosin | nPen m 1, rAni s 3, nBla g 7, rDer p 10 | |
| ATP:guanido phosphotransferase (arginine kinase) | nPen m 2 | |
| Superoxide dismutase | rAsp f 6 | |
| Unique to fungi | Alt a 1 | |
| Non-CG | EF-hand | |
| Bet v 1 like | rAct d 8 | |
| Cysteine-rich secretory protein family (venom antigen) | rPol d 5, rVes v 5 | |
| Trypsin-like serine protease (peptidase S1) | rCan f 5 | |
| Enolase | rAlt a 6 | |
| Transferrin | rGal d 3 | |
| Glycosyl hydrolases family 17 (β-glucanase) | ||
| γ-Thionin (thionin with O-glycans; Art v 1 family) | nArt v 1 | |
| Cupin | nJug r 1 |
Pollen allergens are shown in boldface. Allergen nomenclature is based on that of the International Union of Immunological Societies Allergen subcommittee.PR10, Pathogenesis-related class 10 proteins.
Fig 2Association between sensitization to CGs and clinical outcomes. Error bars represent 95% CIs of the OR shown on a log scale.
Association between sensitization to CGs and clinical outcomes
| Sensitization to: | Current wheeze (OR [95% CI]), | Current asthma (OR [95% CI]), | Current hay fever (OR [95% CI]), | Eczema (OR [95% CI]), |
|---|---|---|---|---|
| CG1 | 1.48 (0.77-2.84), .24 | 1.61 (0.84-3.10), .15 | 1.10 (0.57-2.13), .78 | |
| CG2 | 1.62 (0.91-2.90), .10 | |||
| CG3 | 1.15 (0.44-3.00), .77 | 2.00 (0.89-4.49), .09 |
Values in boldface indicate statistical significance.
Fig 3Estimated marginal means for FEV1 (percent predicted; A) and eNO (B) in those sensitized to CGs.